Published on 30/11/2025

Storyboards for PPQ/CPV in Inspections: A Comprehensive Guide

Introduction to PPQ/CPV in Biosimilars

Process Performance Qualification (PPQ) and Continuous Process Verification (CPV) are critical components in the lifecycle management of biosimilar products. They ensure that processes consistently deliver products meeting predetermined quality attributes. In recent years, regulatory authorities such as the FDA and EMA have emphasized the importance of robust comparability assessments between reference biologics and their biosimilars. This guide provides a detailed, step-by-step approach to develop effective storyboards for PPQ and CPV, focusing on analytical comparability, CQA mapping, fingerprint analytics, process drift monitoring, and equivalence testing.

Step 1: Understanding Key Terms and Concepts

Before diving into the storyboarding process, it’s crucial to clarify some essential terms and concepts:

• PPQ (Process Performance Qualification): The stage of qualification that verifies if a manufacturing process operates within its defined operating ranges to consistently produce products of acceptable quality.
• CPV (Continuous Process Verification): A regulatory expectation where the quality of a product is continuously monitored throughout its production lifecycle.
• CQA Mapping (Critical Quality Attributes): A systematic approach to identify and validate the essential quality attributes of biosimilars that need to be monitored and controlled during production.
• Fingerprint Analytics: A method used to develop a quantitative profile of critical quality attributes over the lifecycle of the biosimilar, ensuring comparability to the reference product.
• Process Drift Monitoring: The ongoing assessment of manufacturing parameters to identify any deviations over time that may affect product quality.
• Equivalence Testing: A statistical approach to demonstrate that a biosimilar is highly similar to a reference product with no clinically meaningful differences in safety or efficacy.

Having a clear understanding of these terms will facilitate the development of effective storyboards for inspections and facilitate compliance with regulatory expectations.

Step 2: Framework for Developing Storyboards

The process of developing storyboards for PPQ and CPV in biosimilars involves several critical steps:

2.1 Identify and Engage Stakeholders

Start by identifying all relevant stakeholders involved in the development and manufacturing process of biosimilars. These may include:

• Quality Assurance professionals
• Regulatory Affairs specialists
• Clinical Operations teams
• Production and Engineering teams

Engaging stakeholders early will ensure alignment on objectives and expectations.

2.2 Define Objectives and Regulatory Requirements

Establish clear objectives for your PPQ and CPV strategy in line with regulatory expectations outlined in FDA and EMA guidelines. Particular focus should be placed on:

• Essential quality attributes that require monitoring
• Regulatory documentation such as Q5E and Q6B specifications

By defining objectives, you can establish specific metrics and monitors for your storyboards.

Step 3: Constructing the Storyboard

The storyboard should visually represent the entire PPQ/CPV strategy, illustrating critical processes, data flows, and decision points. Here are components to include:

3.1 Overview of Biomanufacturing Processes

Include diagrams or flowcharts that detail the biomanufacturing processes from upstream to downstream steps. This visual overview will help reviewers understand the production workflow in a regulatory inspection.

3.2 Highlighting Critical Quality Attributes

Specify the Critical Quality Attributes (CQAs) identified during CQA mapping. Include how each CQA will be monitored through PPQ and CPV.

• For example, a CQA might be the potency of the biosimilar, which should be regularly assessed.

3.3 Integrating Analytical Comparability Data

Integrate data from fingerprint analytics throughout the lifecycle of the product. This demonstrates the continual comparability of the biosimilar to its reference product.

3.4 Documentation for Inspections

Ensure that your storyboard includes a summary of all supporting documentation, detailing the approach taken for equivalence testing and providing bridging justifications where necessary. The inclusion of this documentation prepares you for any FDA, EMA, or MHRA inspection.

Step 4: Monitoring Process Drift

Process drift monitoring is vital to ensuring the ongoing quality of biosimilars. Establish a strategy for continual monitoring, involving:

• Routine analyses and trending of CQAs to identify any deviations.
• Data from real-time monitoring systems for critical parameters.
• Performing periodic reviews and updates of the PPQ/CPV plan in response to observed trends.

Step 5: Reporting and Compliance

A comprehensive report should be compiled based on the data and insights gathered throughout the PPQ and CPV processes. This report serves multiple purposes:

• It ensures compliance with regulatory expectations.
• It provides a summary of findings for internal stakeholders.

Regulatory agencies require documentation that includes CQA mapping results, fingerprint analytics, and any observations on process drift. This documentation is crucial when applying for approvals or during inspections.

Step 6: Continuous Improvement and Training

To promote a culture of compliance and quality, continuous improvement and training should be ingrained within the PPQ/CPV strategy. This can include:

• Regular training sessions for staff involved in PPQ/CPV activities.
• Incorporating feedback from past inspections to improve processes.
• Reviewing and revising the PPQ/CPV plan based on new regulatory guidance or scientific advancements.

Conclusion

Developing effective storyboards for PPQ and CPV in biosimilars not only enhances the understanding of these critical processes but also prepares for regulatory inspections. By clearly mapping out processes, critical quality attributes, and compliance strategies, pharmaceutical professionals can ensure that their products meet the high standards required by regulatory authorities such as the FDA and EMA. The integration of analytical comparability, process drift monitoring, and ongoing training into the PPQ/CPV strategy will further promote product quality and efficacy, establishing a robust framework for biosimilar development.